frunexian

Frunexian (formerly known as HSK36273 and EP-7041) is a potent and selective small molecule inhibitor of activated coagulation factor XI (FXIa). It acts by selectively blocking the intrinsic pathway of blood coagulation, thereby inhibiting the amplification of the clotting cascade without significantly affecting normal hemostasis through the extrinsic pathway. Frunexian is being developed primarily as an anticoagulant therapy for conditions requiring prevention or treatment of thrombosis, including use in continuous renal replacement therapy (CRRT). The drug has demonstrated favorable safety profiles with no significant bleeding events in phase I studies and predictable pharmacokinetics. It is administered intravenously and has reached phase II clinical trials. The developer is Haisco Pharmaceutical Group[1][2][4][7].

Brand names

Frunexian

Other names

frunexian hydrochloride